- Home
- FMTO vs CERO Comparison
FMTO vs CERO Comparison
Compare FMTO & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMTO
- CERO
- Stock Information
- Founded
- FMTO 2000
- CERO 2017
- Country
- FMTO Israel
- CERO United States
- Employees
- FMTO N/A
- CERO 8
- Industry
- FMTO
- CERO
- Sector
- FMTO
- CERO
- Exchange
- FMTO NYSE
- CERO Nasdaq
- Market Cap
- FMTO 3.0M
- CERO 3.7M
- IPO Year
- FMTO N/A
- CERO N/A
- Fundamental
- Price
- FMTO $4.60
- CERO $0.45
- Analyst Decision
- FMTO
- CERO Buy
- Analyst Count
- FMTO 0
- CERO 2
- Target Price
- FMTO N/A
- CERO $3.00
- AVG Volume (30 Days)
- FMTO 35.5K
- CERO 993.4K
- Earning Date
- FMTO 08-06-2025
- CERO 05-15-2025
- Dividend Yield
- FMTO N/A
- CERO N/A
- EPS Growth
- FMTO N/A
- CERO N/A
- EPS
- FMTO N/A
- CERO N/A
- Revenue
- FMTO $620,978.00
- CERO N/A
- Revenue This Year
- FMTO N/A
- CERO N/A
- Revenue Next Year
- FMTO N/A
- CERO N/A
- P/E Ratio
- FMTO N/A
- CERO N/A
- Revenue Growth
- FMTO N/A
- CERO N/A
- 52 Week Low
- FMTO $3.85
- CERO $0.40
- 52 Week High
- FMTO $6,927.50
- CERO $102.00
- Technical
- Relative Strength Index (RSI)
- FMTO N/A
- CERO 35.19
- Support Level
- FMTO N/A
- CERO $0.42
- Resistance Level
- FMTO N/A
- CERO $0.50
- Average True Range (ATR)
- FMTO 0.00
- CERO 0.05
- MACD
- FMTO 0.00
- CERO 0.00
- Stochastic Oscillator
- FMTO 0.00
- CERO 24.77
About FMTO FEMTO TECHNOLOGIES INC
Femto Technologies Inc is an integrated software company. It owns and markets Benefit CRM, a proprietary customer relationship management CRM software product enabling small and medium sized businesses to optimize their day to day business activities such as sales management, personnel management, marketing, call center activities, and asset management.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.